Company news

GSK plc news in 2026

GSK plc's news releases, calls and decks from 2026, newest first.

View company

GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)

July 17, 2026

Camlipixant phase III results update

July 17, 2026

GSK completes acquisition of Nuvalent, Inc.

July 15, 2026

GSK completes acquisition of Nuvalent, Inc

July 15, 2026

GSK: Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

July 13, 2026

Positive Jemperli data in dMMR/MSI-H rectal cancer

July 13, 2026

GSK licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

July 10, 2026

Hansoh positive Phase III results for Riz-Rez

July 10, 2026

Roy Jakobs to join GSK Board as Non-Executive Director

July 9, 2026

Directorate change

July 9, 2026

GSK announces tender offer to acquire Nuvalent

June 24, 2026

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

June 17, 2026

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

June 17, 2026

cUTI oral antibiotic Tebipenem approved by US FDA

June 17, 2026

Momelotinib orphan drug designations for VEXAS

June 12, 2026

The Franklin Institute and GSK Celebrate 40 Years of GSK Science in the Summer™ with New "Be A Chemist!" Theme and Program Expansion

June 10, 2026

Dr Hal Barron – New Directorship

June 9, 2026

The Biotech Growth Trust PLC - GSK plc to acquire BIOG portfolio company, Nuvalent, Inc.

June 9, 2026

GSK enters agreement to acquire Nuvalent, Inc.

June 9, 2026

Nucala (mepolizumab) approved in Canada for use in adults with chronic obstructive pulmonary disease (COPD)

June 1, 2026

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

May 28, 2026

Positive Phase 3 data for bepirovirsen

May 28, 2026

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA

May 26, 2026

Q2 2026 Results Date Confirmed - 28 July 2026

May 22, 2026

Japan MHLW approves Arexvy for adults 18-49 AIR

May 18, 2026

Benlysta Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

May 15, 2026

Collaboration with CTTQ for bepirovirsen

May 11, 2026

GSK - final tranche of share buyback programme

May 11, 2026

2026 Remuneration Policy

May 6, 2026

GSK presents latest respiratory research to advance patient care at ATS 2026

May 6, 2026

Q1 2026 results transcript

April 30, 2026

Q1 results lower year on year, as expected; Comprehensive action plan underway to address market challenges

April 29, 2026

Human Papillomavirus Market Research Report 2025-2035, Competitive Analysis of Key Players - GlaxoSmithKline, Merck, and Serum Institute of India

April 28, 2026

Bepirovirsen priority review US filing acceptance

April 28, 2026

Efimosfermin granted US/EU regulatory designations

April 27, 2026

TESARO update on AnaptysBio Inc. litigation

April 27, 2026

Blenrep approved in China for 2L+ multiple myeloma

April 20, 2026

GSK completes acquisition of 35Pharma Inc.

April 15, 2026

GSK presents positive data for BEHOLD 1 B7 H4 ADC

April 13, 2026

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers

April 12, 2026

The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day

April 10, 2026

Q1 2026 pre announcement aide memoire

April 9, 2026

Exdensur approved for CRSwNP in China

April 8, 2026

ViiV completes changes to minority shareholding

April 1, 2026

Bepirovirsen accepted for review in China

March 30, 2026

Exdensur approved for severe asthma in China

March 30, 2026

Bepirovirsen accepted for review by the EMA

March 27, 2026

Inflammation Supplements Market Expands Across Europe and Asia-Pacific with GSK, Pfizer, and Himalaya Wellness

March 26, 2026

Articles of Association - Proposed Amendments

March 25, 2026

Proxy Form 2026

March 25, 2026

← Newer news releases · Older news releases →

Calls in 2026

Decks in 2026